$ 3,400,000 - Sole Placement Agent
CHT Holdings (PRIVATE)
$ 10,000,000 - Placement Agent
Variant Pharmaceuticals (PRIVATE)
$ 11,500,000 - Placement Agent
Social Reality (SRAX)
$23,500,000 - Secondary Offering
Noble Life Science Partners is focused exclusively on the biotechnology, specialty pharmaceutical and medical technology industries. Visit the Noble LSP website
We are a research-driven investment bank focused on small cap emerging growth companies in the healthcare, technology, media, transportation & logistics and natural resources sectors. That's what we are. Who we are is what makes us different.
Our people are talented, dedicated, experienced professionals who come together with a common cause; advising on long-term client-solutions by employing innovative, collaborative and responsive strategies. We're passionate and personable. We approach things from our clients' perspective.
We know that developing lasting relationships is reliant upon putting our clients' interests before ours. We understand the impact of our services. Insightful advisory and effective capital procurement can change lives. Empowering our clients to create employment, engineer technological and medical breakthroughs, producing products and services that lay the foundation for the future. For more than 30 years these have been our guiding principles. While much has changed over the three decades since we began, these core values and our reputation have not. Our clients must know what to expect from us. Then we can strive to exceed expectations.
Our investment decisions are driven by experienced analysts, conducting disciplined and in-depth rigorous research and analysis. By combining our experience with this comprehensive research process we are able to publish thoughtful fundamental research, generating actionable investment ideas for our institutional clients.
Our Life Science Advisory Boards is a strategic resource whose experience, relationships and knowledge are utilized throughout NOBLE Capital Markets to enhance all service offerings. Through the Advisory Board, we have access to world-class professionals for substantive advice regarding new discoveries, technologies, products, services and developments.
Mr. Pronk joined NOBLE Capital Markets in 1988 as Chief Operating Officer. In 1995, he became owner. Mr. Pronk began his career in Europe in 1986 on the European Options Exchange (EOE). Mr. Pronk has over 25 years of experience working with IPOs, Secondary Offerings, Private Placements and Mergers and Acquisitions. During his career he has served as Director or Advisor to numerous privately held and publicly traded companies. Mr. Pronk is a graduate of the Netherlands Institute of Banking and Finance, and holds various FINRA licenses. Mr. Pronk is the current Chairman, and principal owner of Privaira, a Boca Raton based private aviation company.
Nico P. Pronk, CEO / President
Mr. Pinvidic joined NOBLE Capital Markets in 2002 bringing more than 25 years of senior management experience in corporate communications, marketing, sales and product development across several business sectors including oil & gas, healthcare / biotechnology, retail and consumer goods manufacturing. Throughout his career he has co-founded two public companies and created a consumer products company that, in 1999, was recognized by Women's Wear Daily as developing the most innovative and successful product launch of that year. Mr. Pinvidic has also been recognized by organizations such as the International Association of Business Communicators (IABC), the International Package Design Awards (IPDA), the Design Council of Canada, and the Toronto Art Director's Association for his work on annual reports, corporate identity programs, packaging design and consumer advertising. Mr. Pinvidic is responsible for all aspects of corporate identity, marketing and the management of the various conferences sponsored by NOBLE Capital Markets.
Mark Pinvidic, Managing Partner
Media and Entertainment
Michael Kupinski joined NOBLE Capital Markets in 2007 as director of research and Media & Entertainment senior research analyst. Before joining the company, he was the vice president and Media & Entertainment analyst for A.G. Edwards for twenty-three years. He is a member of the National Cable Television Society Foundation and the National Association of Broadcasters. He was a columnist for the Pulse of Radio, a broadcast radio trade publication, and a trustee of the National Television Academy. The Wall Street Journal selected Mr. Kupinski as a 'Best on the Street' All-Star Analyst in 1996, 1997, 1999, 2001, 2003, and in 2004 for his stock picking skills. Mr. Kupinski is widely quoted in national publications such as USA Today, The Wall Street Journal, and The New York Times, and is a frequent guest on cable news networks CNBC, CNN, and Bloomberg TV.
Michael Kupinski, Director of Research, Senior Media & Entertainment Analyst
Mr. Giles brings to NOBLE Capital Markets more than 30 years of investment banking and capital markets experience. Most recently Mr. Giles was head of the technology group at Stifel Nicolaus and prior to that spent 16 years at A.G. Edwards as head of its emerging growth group that included both Edwards' technology and healthcare practices. During his career he has executed over 100 public financings raising over $4 billion for his clients, including IPOs for companies such as VMWare, COMPAQ, Cardica and ExecuStay. He also has overseen numerous M&A transactions on the buy side as well as the sell side. Mr. Giles received his AB from Harvard College and his MBA from the Harvard Business School. Mr. Giles holds various FINRA licenses and works out of the company's Boston Office.
Richard Giles, Managing Director / Head of TMT and Natural Resources Investment Banking Group
Nathan Cali has more than 14 years of combined healthcare, biotechnology and pharmaceutical experience. Mr. Cali was previously a sell-side analyst for 9 years with expertise and publications cover many areas of biotechnology, specialty pharmaceuticals (branded and generics), medical devices, and regenerative medicine. He has been quoted in most business journals including Reuters, BioMed Reports and the Washington Business Journal. Mr Cali is the co-founder of Variant Pharmaceuticals an early stage biotechnology company advancing orphan drugs for the treatment of renal diseases. He is currently a Committee Member at the Moffitt Cancer Center for Commercialization and a member of the Development Board of Palm Beach County. Mr. Cali started his career in healthcare at Andrx Corporation, a biotechnology and specialty pharmaceuticals company known for its expertise in the development of controlled-release drugs. Mr. Cali was a corporate manager dealing in finance, state taxation, corporate governance, patents, drug distribution and business development for the biotechnology firm. Andrx was purchased by Watson Pharmaceuticals in 2006 for $2.0 billion in cash. Prior to joining NOBLE, Mr. Cali gained investment experience as a portfolio account analyst/manager at Franklin Templeton Investments. Mr. Cali holds a B.S. in Finance from The Florida State University and an M.B.A. in Finance from Nova Southeastern University. Nathan also currently holds series 7, 79, 86, and 87 FINRA designations.
Nathan Cali, Managing Director, Head of Healthcare Investment and Merchant Banking
Portfolio Manager/Institutional Sales
Dennie joined NOBLE’s Private Client Group in 2002 and has provided wealth management services to NOBLE Clients for over 17 years. He holds a bachelor’s degree in Business Management and Administration from Northeastern State University in Oklahoma and an International Marketing and Management degree from G.K. van Hogedorp University in the Netherlands. In addition to holding various FINRA licenses, Mr. Ceelen has his Life Insurance and Annuity license and is a Certified Financial Planner (CFP). He is also a committee member of The Society of Financial Service Professionals.
Dennie Ceelen, CFP®, Private Client Group